Maintenance of Long-Term Safety and Efficacy of Cannabidiol Treatment in Dravet Syndrome: Results of the Open-Label Extension Trial (GWPCARE5)

被引：0
|
作者：
Devinsky, O. [1 ]
Nabbout, R. [2 ]
Miller, I. [3 ]
Laux, L. [4 ]
Zolnowska, M. [5 ]
Wright, S. [6 ]
Roberts, C. [6 ]
机构：
[1] NYU, Comprehens Epilepsy Ctr, New York, NY USA
[2] Necker Enfants Malad Hosp, Paris, France
[3] Miami Childrens Hosp, Miami, FL USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA
[5] Ctr Med Plejady, Krakow, Poland
[6] GW Res Ltd, Cambridge, England
来源：
EPILEPSIA | 2018年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
p149
引用
收藏
页码：S73 / S73
页数：1
相关论文
共 50 条
  • [1] Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5)
    Laux, L.
    Devinsky, O.
    Miller, I
    Nabbout, R.
    Zolnowska, M.
    Wright, S.
    Roberts, C.
    ANNALS OF NEUROLOGY, 2018, 84 : S344 - S344
  • [2] Maintenance of Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome (DS): Results of the Open-Label Extension (OLE) Trial (GWPCARE5)
    Miller, Ian
    Devinsky, Orrin
    Nabbout, Rima
    Laux, Linda
    Zolnowska, Marta
    Wright, Stephen
    Roberts, Claire
    NEUROLOGY, 2018, 90
  • [3] Long-Term Safety And Efficacy Of Add-On Cannabidiol (CBD) Treatment In Patients With Dravet Syndrome In An Open-Label Extension Trial (GWPCARE5)
    Nabbout, R.
    Halford, J.
    Scheffer, I. E.
    Sanchez-Carpintero, R.
    Malawsky, Y. Shiloh
    Wong, M.
    Checketts, D.
    VanLandingham, K.
    EPILEPSIA, 2019, 60 : 63 - 63
  • [4] Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Patients with Dravet Syndrome (DS): 3-Year Interim Results of an Open-Label Extension (OLE) Trial (GWPCARE5)
    Halford, Jonathan J.
    Scheffer, Ingrid
    Nabbout, Rima
    Sanchez-Carpintero, Rocio
    Malawky, Yael Shiloh
    Wong, Matthew
    Checketts, Daniel
    Dunayevich, Eduardo
    NEUROLOGY, 2020, 94 (15)
  • [5] Long-Term Safety and Efficacy of Cannabidiol (CBD) Treatment in Dravet Syndrome: Results Overall and for Patients Completing 1-3 Years of an Open-Label Extension (GWPCARE5)
    Nabbout, R.
    Sanchez-Carpintero, R.
    Halford, J. J.
    Shiloh-Malawsky, Y.
    Scheirer, I. E.
    Wong, M.
    Checketts, D.
    Dunayevich, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 435 - 435
  • [6] Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Lennox Gastaut Syndrome in an Open-label Extension Trial (GWPCARE5)
    Patel, Anup
    Gil-Nagel, Antonio
    Chin, Richard
    Mitchell, Wendy
    Perry, M. Scott
    Weinstock, Arie
    Roberts, Claire
    Whyte, Lauren
    VanLandingham, Kevan
    NEUROLOGY, 2019, 92 (15)
  • [7] Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results from Open-label Extension Trial (GWPCARE5)
    Halford, Jonathan
    Marsh, Eric
    Mazurkiewicz-Beldzinska, Maria
    Gunning, Boudewjin
    Checketts, Daniel
    Roberts, Claire
    Thiele, Elizabeth
    NEUROLOGY, 2018, 90
  • [8] Maintained Safety and Efficacy of Cannabidiol in a Long-Term Open-Label Trial in Patients with Lennox-Gastaut Syndrome (GWPCARE5)
    Marsh, E.
    Mazurkiewicz-Beldzinska, M.
    Halford, J.
    Gunning, B.
    Checketts, D.
    Roberts, C.
    Thiele, E.
    EPILEPSIA, 2018, 59 : S9 - S9
  • [9] Long-term Safety and Efficacy of Cannabidiol (CBD) in Patients with Lennox-Gastaut Syndrome (LGS): Results of the Open-label Extension (OLE) Trial (GWPCARE5)
    Thiele, E.
    Marsh, E.
    Halford, J.
    Mazurkiewicz-Beldzinska, M.
    Gunning, B.
    Checketts, D.
    Roberts, C.
    ANNALS OF NEUROLOGY, 2018, 84 : S336 - S336
  • [10] Long-Term Safety And Efficacy Of Add-on Cannabidiol (CBD) Treatment in Patients With Lennox-Gastaut Syndrome In An Open-Label Extension Trial (GWPCARE5)
    Chin, R.
    Patel, A.
    Gil-Nagel, A.
    Mitchell, W.
    Perry, M. S.
    Weinstock, A.
    Whyte, L.
    VanLandingham, K.
    EPILEPSIA, 2019, 60 : 63 - 64
12345